Found 7 articles for: "Adalimumab"
Risankizumab Associated With Lower Incident Depression and Sleep Disorders in Psoriasis: A TriNetX Study
August 2026 | Volume 25 | Issue 8 | Editorials | 762 | Copyright © August 2026
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene
August 2025 | Volume 24 | Issue 8 | Original Article | 795 | Copyright © August 2025
Background: Hyperkeratotic plaque psoriasis represents a distinct morphological variant that is difficult to treat with topical therapies because thick lesions may impede the pen...
Read MoreComparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison
August 2025 | Volume 24 | Issue 8 | Original Article | 788 | Copyright © August 2025
Background: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus ...
Read MoreTwo-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreIncreased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa
June 2023 | Volume 22 | Issue 6 | Features | 615 | Copyright © June 2023
Background: TNF-inhibitor adalimumab 40 mg/week (ADA40) is the only approved treatment for hidradenitis suppurativa (HS); however, it is not uniformly effective. Despite a high p...
Read MoreConcurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease
November 2022 | Volume 21 | Issue 11 | Case Reports | 1256 | Copyright © November 2022
Tumor necrosis factor (TNF) antagonists have revolutionized management for various autoimmune and inflammatory conditions, including rheumatoid arthritis (RA), inflammatory bowel disease, hidradenitis...
Read MoreLong-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
April 2022 | Volume 21 | Issue 4 | Original Article | 399 | Copyright © April 2022
Background: There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.